Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema. Banerji A, Craig T, Sitz K, Li HH, et al. J Allergy Clin Immunol 2026;157:1127-1135.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Banerji A, Craig T, Sitz K, Li HH, et al. Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema. J Allergy Clin Immunol 2026;157:1127-1135.
PMID: 41794053